Adaptive CEO Chad Robins joins distinguished panel at Cancer Advance Conference at Harvard Medical School. In the panel, “Next Generation – Omics Technologies: Innovation in Rx/Dx Strategies,” Mr. Robins will elucidate how Adaptive’s assays are being incorporated into clinical trials in hematologic malignancies and solid tumors.
Latest Press Releases
Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board
Adaptive announced today that it has established a Scientific Advisory Board to provide strategic and clinical guidance for the implementation of its clinical diagnostic suite of assays in the diagnosis and monitoring of patients with leukemia and lymphoma. The initial focus of the SAB will be to support the utility of clonoSEQ, Adaptive’s highly accurate and sensitive NGS assay for monitoring Minimal Residual Disease (MRD) in patients with blood cancer.
Adaptive was featured in the recent issue of Seattle Business under the headline: Adaptive Biotechnologies’ ‘Tools of the Trade’. Local firm takes a huge step forward in helping scientists understand the complexities of the human immune system.
Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer
Adaptive is pleased to announce the appointment of Brian Hansen as Chief Commercial Officer (CCO). The addition of Brian to the Company’s expanding Executive Leadership Team follows recent key hires from leading global healthcare companies, including Dean Schorno (CFO) and Kathleen Determann (General Counsel) from Genomic Health and Sean Nolan (CTO) from Microsoft’s Healthvault.
Adaptive CEO joins distinguished panel at Genomics 2.0 Conference to Discuss Company’s Pipeline of Cancer Diagnostics
Adaptive announced today that Chad Robins, its Founder and Chief Executive Officer, is participating in a panel discussion this morning at the prestigious Genomics 2.0 Conference in Park City, Utah. The panel, entitled “Changing the Game in Oncology,” includes other industry notables Randy Scott, CEO of Invitae, Steven Kafka, COO of Foundation Medicine, and Ronnie Andrews, Division President at Thermo Fisher.
Veteran Microsoft Executive and Distinguished Engineer, Sean Nolan, joins Adaptive Biotechnologies as Chief Technology Officer
Adaptive is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company’s expanding Executive Leadership Team. Mr. Nolan’s hire, the second management hire this month, represents Adaptive’s continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.
Study Reports clonoSEQ Detects Residual Disease in 33% More Childhood Leukemia Patients Compared to Current Standard of Care Laboratory Test
Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling
Veteran Genomic Health Executive, Dean Schorno, CPA, joins Adaptive Biotechnologies as Chief Financial Officer
Adaptive is pleased to announce the appointment of Dean Schorno, CPA,. as Chief Financial Officer and the newest member of the Company’s expanding Executive Leadership Team.
Adaptive Biotechnologies and Collaborators to Present Data Advancing the Clinical Utility of Immunosequencing at the 50th Annual Meeting of the American Society of Clinical Oncology
Adaptive and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology.